Navigation Links
World-renowned nanotechnology expert proves there is big potential in the smallest of matter

CAMBRIDGE, Mass. (June 24, 2009) For Professor Chad Mirkin, good things come in small packages specifically one billionth of a meter in size. Yet, as director of Northwestern University's International Institute for Nanotechnology, the impact of Mirkin's work is anything but small. A prolific inventor and entrepreneur, his innovations have the potential to transform the future of medical diagnostics and patient point-of-care and to ignite change across many industries from semi-conductors to healthcare. For his revolutionary discoveries and sizeable contributions to science and invention, Mirkin is awarded the prestigious 2009 $500,000 Lemelson-MIT Prize.

Mirkin, the George B. Rathmann Professor of Chemistry at Northwestern University (NU), will accept the prize and present his accomplishments to the public at the Massachusetts Institute of Technology during the Lemelson-MIT Program's third-annual EurekaFest, a multi-day celebration of the inventive spirit, June 25-27.

As a leader in the burgeoning field of nanotechnology, Mirkin is the author of 380 manuscripts and over 350 patents and applications, and is currently listed as the third most cited chemist over the past decade and the most cited nanomedicine researcher in the world.1,2 "Professor Mirkin's cutting-edge, innovative work is greatly contributing to America's economic competitiveness and will help ensure that the nation remains at the forefront of one of the most promising areas in science," states Congressman Daniel Lipinski of Illinois.

Mirkin is best known for the invention, development and commercialization of two revolutionary technologies the nanoparticle-based medical diagnostic assays underlying the FDA-approved Verigene IDTM system and Dip-Pen Nanolithography (DPN), an ultra high resolution molecule-based printing technique. Both inventions were born, in part, out of Northwestern University's Nanoscale Science and Engineering Center, funded by the National Science Foundation, and conceived, managed and directed by Mirkin. There, Mirkin's research, with the help of NU graduate students and colleagues, has formed the basis of several start-up companies that are helping to bring his inventions from the lab to the market.

Nanotechnology as a Disease Detector

Current medical diagnostic tools make it challenging to understand the identities of molecules circulating in the human bloodstream, which provide early warning signs of disease. Often, a disease isn't detected until an illness has progressed and indicator molecules become visible in higher concentrations. Current genetic testing, often performed in a distant lab, may take weeks to deliver results and authenticate or rule out the presence of a threatening disease or illness an inefficient and costly process with potential negative health consequences.

Mirkin invented a highly precise method of identifying low concentrations of disease-signifying molecules. "In the case of proteins, the test can be thousands of times more sensitive than any commercial protein detection system out there, and has the power to revolutionize medical diagnosis," states Mirkin.

Mirkin commercialized many of the nanoparticle-based medical diagnostic assays through Nanosphere Inc., leading to the development of the Verigene ID System. This innovative biodiagnostic system can test patients for several different disease targets at the same time, on-site in a research laboratory, community hospital, or doctor's office in under an hour.

One of the most promising applications of this technology is in Alzheimer's disease, which presently affects as many as 5.3 million Americans.3 Today, patients can only be posthumously confirmed as having Alzheimer's. Mirkin's bio-barcode test has the potential to evaluate living patients for Alzheimer's by detecting very low concentrations of the protein associated with the disease, allowing for early intervention and potential treatment.

Mirkin's work with nanostructures made of gold has since led to new ventures and the founding of Aurasense, a company focused on developing a novel class of nanotherapeutics that are nontoxic and extremely effective in gene regulation for application in oncology and heart disease.

Manipulating Biological Materials with Dip-Pen Nanolithography

Printing is the cornerstone for many core technologies, including information transfer, electronics, medical diagnostics, and drug discovery. Modern microfabrication processes have made printing on the microscopic scale widely accessible. The challenge of creating flexible tools that allow one to print on the nanoscopic scale led Mirkin to invent Dip-Pen Nanolithography (DPN).

This technology, licensed by NanoInk, can be used to print features of proteins, DNA and other biological materials on surfaces with sub-50 nanometer resolution.

Commercialized in the form of the NscriptorTM, it has become a novel research tool, allowing scientists to better understand how cells interact with surfaces and function, the chemical and physical consequences of miniaturization, and how structures including individual viruses behave at the single particle level. This knowledge is important for learning how viruses infect cells, understanding the chemical and physical differences between healthy and cancerous cells, or discovering the genetic code associated with a new flu virus all of which could lead to new therapeutics and diagnostics. DPN's applications extend even further than this to highly miniaturized polymer- and molecular-based electronics.

Mirkin's latest invention, Polymer-pen lithography, which uses millions of polymer-based tips, is designed to cover a larger surface area and has more commercial applications ranging from computational tools, medical diagnostics like gene chips, and pharmaceutical discovery through combinatorial biomolecule arrays for screening drug candidates.

Engaging and Inspiring Young Scientists

Mirkin also serves as a role model and leader for aspiring young scientists and inventors. Through work with the International Institute for Nanotechnology, Mirkin and his colleagues devise innovative science programs around the country to educate youth including the development of the DiscoverNANO Web site, which introduces young people to nanotechnology. Currently, Mirkin is also working with the Museum of Science and Industry in Chicago to complete a hands-on nanotechnology exhibit.

"Mirkin is an extraordinary scientist who is at the forefront of the growing field of nanotechnology," states Michael J. Cima, faculty director of the Lemelson-MIT Program. "His inventions are paving the way for the emergence of nanotechnology in medicine, with impact that extends far beyond the scientific community. Mirkin is truly deserving of this honor."


Contact: Julie Staadecker
Lemelson-MIT Program

Related medicine news :

1. World-Renowned Neuroscientist Dr. Candace Pert will be Featured Speaker at the Chopra Center's Signature Mind-Body Healing Workshop in San Diego
2. World-renowned neuroscientist visits UTSA on May 5 to discuss the quest for consciousness
3. World-Renowned Golf Instructor David Leadbetter Promotes VaNu
4. World-renowned Instructor of the Healing Practice of Qigong to Teach in Los Angeles Mar. 7 & 8
5. World-Renowned Urologist, J. Francois Eid, M.D., Expands Practice with Increased Treatment of Benign Prostate Hyperplasia (BPH)
6. World-Renowned Physicians Converge on Methodist Dallas Medical Center for Largest Live Demonstration of Its Kind in Texas
7. World-Renowned Scientists to Lead Immunology Course
8. World-renowned bioengineers to record history of medical inventions
9. World-Renowned Therapist Joins The Center for Children and Families In Its Work With the Nations Poorest Families
10. Report: Asbestos Litigation Disaster for Investors Could Be Repeated With Nanotechnology Unless SEC and FASB Close Eight Major Loopholes Now Preventing Honest Disclosures
11. Scientists advance safety of nanotechnology
Post Your Comments:
Related Image:
World-renowned nanotechnology expert proves there is big potential in the smallest of matter
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is ... emergency ambulance transport experience for the millions of people who require these medical ... the taxi industry through the use of technology. Now, SmartEMS has put forth ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/26/2016)... ... 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping to ... app. The fitness app plans to fix the two major problems leading the fitness industry ... fits all type program , They don’t eliminate all the reasons people quit ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
(Date:6/23/2016)... HILLS, Calif. , June 23, 2016 Any ... the many challenges of the current process. Many of them ... because of the technical difficulties and high laboratory costs involved. ... have to offer it at such a high cost that ... afford it. Dr. Parsa Zadeh , founder ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology: